The 2025 study is not alone. Several additional studies paint a similar picture of potential benefit.
1. Systematic Review: Stem-Cell Therapy in Children with Autism (Qu et al., 2022)
This scientific review analyzed several clinical trials and found:
Researchers emphasized that while more controlled studies are needed, the early results are encouraging.
2. Phase II Clinical Trial (2025): Stem-Cell Therapy for Core Autism Symptoms
A recent controlled clinical study published in Stem Cell Research & Therapy (2025) reported that stem-cell treatment led to:
The authors described these changes as “substantial improvements in core autism symptoms.”
3. Mechanistic Evidence: How Stem Cells Improve Brain Health
A series of laboratory and animal studies show that MSCs can:
These biological effects mirror what clinicians observe in many children after treatment: greater calmness, more connection, better communication, and improved flexibility.
In 2025, a team led by Georg S. Kobinia and Philipp R. Heuberer published one of the largest real-world analyses of stem-cell therapy in autism to date.
What they did?
What happened?
Across the entire group, the results were striking:
Why this matters?
This study suggests that improvements in communication, behavior, and daily functioning may be possible when the body’s own healing cells are placed into the environment where they are needed most — the cerebrospinal fluid surrounding the brain and spinal cord.
1. MSC Therapy for Spastic CP (Wang et al., 2020)
Umbilical – Cord MSC injections led to:
2. Korean Phase II Trial (Kang et al., 2015)
Using donor cord blood STEM Cells + Erythropoietin:
3. Duke University Trials (Sun et al., 2017; Korgaonkar et al., 2020)
These landmark studies showed that children treated with their own umbilical cord blood or donor cord-derived MSCs demonstrated:
Effects were stronger with higher doses of STEM Cells.
4. Meta-Analyses (2020–2024)
Across many trials:
These findings strongly support stem cells as a promising biological treatment for CP.
1) Expanded MSCs – Modern High-Dose Regeneration
Studies such as Awidi et al. 2024 show that administering large amounts of expanded stem cells – either directly at the lesion site or intrathecally – leads to clear neurological improvements:
Additional work, such as that by Vaquero et al., demonstrates that repeated intrathecal MSC injections (e.g., three times 100 million cells) produce especially strong effects.
Newer analyses confirm this on a broad scale:
STEM Cell Therapy leads to improvement of at least one ASIA grade in nearly half of all treated patients.
(Meta-analysis, Shang et al., BMC Medicine 2022)
2) Autologous Expanded Adipose-Derived Stem Cells – the CELLTOP Studies (Mayo Clinic, USA)
The renowned CELLTOP program, led by Bydon et al. (2020–2024), is considered a milestone.
Key features:
The highlight:
In the most recent analysis (Nature Communications, 2024), 7 out of 10 patients improved their AIS classification – a true neurological advancement.
This confirms:
Autologous expanded stem cells can sustainably regenerate the spinal cord.
3) Autologous Bone Marrow Stem Cells (BMSC)
In landmark studies such as Satti et al. (2016, Cytotherapy), patients receiving their own bone marrow stem cells demonstrated:
These findings have been replicated repeatedly in numerous publications, showing:
This form of therapy clearly activates spinal cord repair.
(References: Satti et al. 2016; Schumacher et al. 2020; Liu et al. 2025)
MSC Therapy: Improvements in Function, Inflammation & MRI Markers
Uccelli, Karussis, Atkins & others (Phase I/II Studies)
Across several trials involving MSC injections (intravenous or intrathecal):
A 2021 meta-analysis showed MSC therapy is consistently safe and associated with functional improvement in progressive MS.
HSCT: One of the Most Effective Treatments for Progressive MS
Burt et al., JAMA 2019 — Landmark Randomized Trial
This trial compared standard MS drugs vs. HSCT.
Results were dramatic:
For some patients, HSCT represents the closest thing to a “reset button” for the immune system.
Remyelination Trials
Li et al., 2020–2024
Early-phase studies show that stem cells may:
This line of research is expanding quickly.
1. Neural Stem Cell Trial (NSI-566) — Glass et al., 2016–2021
In these groundbreaking trials:
Most importantly: The treatment was safe and showed signs of slowing functional decline.
2. Autologous Bone-Marrow MSC Trials (Satti, Karussis, Blanquer)
These studies consistently show:
3. BrainStorm NurOwn® Trials (Phase II and III)
NurOwn is an MSC-based therapy designed to release high levels of neurotrophic (healing) factors.
Findings include:
Although the Phase III trial did not meet FDA approval criteria, many researchers continue to view NurOwn as a scientifically promising approach that warrants further study.
4. Mesenchymal Stem Cell (MSC) Trials — Petrou et al., 2016–2020
This group performed repeated intrathecal MSC injections.
Results showed:
Patients receiving higher doses often showed better stabilization compared to controls.
1. Mesenchymal Stem Cells (MSCs): Anti-Inflammation & Tissue Repair
MSCs from bone marrow, fat tissue, or umbilical cord have been shown to:
Clinical studies across multiple conditions (osteoarthritis, autoimmune disease, frailty, heart disease) consistently show:
These benefits directly relate to slower aging and better resilience.
2. Stem Cells for Immune System Rejuvenation
Aging weakens the immune system, increasing:
Stem-cell therapies — especially hematopoietic stem cells (HSCs) — have demonstrated:
In longevity, a “younger” immune system is essential for protection and vitality.
3. Umbilical Cord Stem Cells: Potent Youth Signals
Umbilical cord tissue and cord-blood stem cells are rich in:
Human studies show that cord-derived MSCs can:
These young cells appear to “reawaken” older tissues and shift the internal environment toward youthful regeneration.
4. Exosome Therapy: The Future of Cell-Free Regeneration
Exosomes — the signaling packets released by stem cells — are emerging as a powerful longevity tool. They can:
Because exosomes do not divide, they avoid some of the regulatory challenges of full stem-cell products while preserving many of their benefits.
1. Jo et al., 2014 (South Korea)
Intra-articular Injection of Adipose-Derived Mesenchymal Stem Cells for Knee Osteoarthritis (Phase I/II Trial)
What this means:
Fat-derived STEM Cells can safely reduce symptoms and may help repair cartilage.
2. Emadedin et al., 2012 & 2015 (Iran)
Autologous Bone-Marrow Stem Cells in Knee Osteoarthritis
What this means:
Your own bone marrow cells may help rebuild portions of damaged joint surfaces.
3. Pers et al., 2016 (France)
Adipose MSC Injection for Knee OA
What this means:
A one-time treatment may provide long-lasting relief.
4. Matas et al., 2019 (Chile)
Allogeneic MSCs for Knee OA
What this means:
Even donor (off-the-shelf) STEM Cells may help reduce inflammation and pain.
5. Freitag et al., 2019 (Australia)
MSC Therapy vs. Standard Treatment
What this means:
STEM Cells outperform traditional therapy options — without surgery.
Discover the unique advantages of STEM Cell Treatment for your long-term health. Take a moment to complete the form with care, ensuring every required field is filled in so we can offer the most accurate guidance.